Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

192.45 -2.55 (-1.31%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
The Smartest Dividend Stocks to Buy With $300 Right Now
Via The Motley Fool
Topics Energy Government World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'
The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential... 
Via Benzinga
How Is The Market Feeling About AbbVie?
Via Benzinga
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong. 
Via The Motley Fool
Topics Intellectual Property
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. 
Via Stocktwits
Topics Product Recall
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation. 
Via Stocktwits
Topics ETFs Economy Government
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
2 Dividend Stocks to Buy for Decades of Passive Income
Via The Motley Fool
Topics Intellectual Property
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Topics Economy Intellectual Property
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data. 
Via Benzinga
3 Profitable Stocks Skating on Thin Ice
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases. 
Via Stocktwits
Topics Intellectual Property
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Topics Government World Trade
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Artificial Intelligence
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial. 
Via Benzinga
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer
Atogepant had fewer discontinuations in the study involving 545 participants due to adverse events than Topiramate. 
Via Stocktwits
Topics Economy
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Via Benzinga
Topics Artificial Intelligence Initial Public Offering
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged. 
Via Benzinga
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data. 
Via Stocktwits
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in combination with Azacitidine compared to Azacitidine and placebo in the treatment... 
Via Stocktwits
1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.